Business Context and Reporting Period
Maiden Holdings, Ltd. (MHLD), a Bermuda-based holding company focused on insurance and reinsurance, filed a Form 8-K on November 8, 2023, to announce its financial results for the three and nine months ended September 30, 2023. The company operates primarily through two segments: AmTrust Reinsurance and Diversified Reinsurance. The reporting period reflects a run-off strategy for legacy reinsurance portfolios alongside active capital management.
Key Financial Metrics
Quarter Ended September 30, 2023
- Net Loss: $3.5 million ($0.03 per diluted share), compared to a net loss of $8.2 million ($0.09 per share) in Q3 2022.
- Non-GAAP Operating Loss: $11.7 million ($0.12 per share), improved from $21.1 million ($0.24 per share) in Q3 2022.
- Underwriting Loss: $10.9 million, down from $12.6 million in Q3 2022.
- Investment Income: Net investment income rose to $9.0 million (up 36.3% YoY) driven by higher interest rates on floating-rate assets.
- Book Value: $2.60 per share; Adjusted Book Value (including deferred gain on retroactive reinsurance) was $3.16 per share.
- Total Assets: $1.58 billion, a decrease of $269.4 million from year-end 2022.
Nine Months Ended September 30, 2023
- Net Loss: $17.8 million ($0.18 per share), compared to net income of $19.2 million in the same period of 2022 (which included a $28.2 million gain from preference share repurchases).
- Non-GAAP Operating Loss: $15.2 million ($0.15 per share), compared to $11.4 million ($0.13 per share) in 2022.
- Underwriting Loss: $28.4 million, compared to $19.4 million in 2022.
- Investment Income: Net investment income increased to $29.1 million (up 39.5% YoY).
- Shareholders' Equity: $263.2 million; Adjusted Shareholders' Equity was $319.8 million.
Material Changes vs. Prior Period
- Adverse Loss Development: The primary driver of underwriting losses was adverse prior year loss development of $7.8 million in Q3 2023 (vs. $0.8 million in Q3 2022). This included $6.0 million in the AmTrust segment (European Hospital Liability) and $1.9 million in the Diversified segment.
- Investment Performance: Investment results improved significantly due to rising interest rates. 37.8% of fixed income investments are now floating-rate, boosting yields to 4.3% annually in Q3 2023 from 2.2% in Q3 2022.
- Premiums: Net premiums written increased to $8.6 million in Q3 2023 from $5.2 million in Q3 2022, largely due to lower negative cession adjustments in the AmTrust segment.
- Capital Actions: The company repurchased 520,475 common shares in Q3 2023 and 820,105 shares for the nine-month period. Additionally, 5,567 Senior Notes were repurchased.
Guidance, Outlook, and Risks
- Management Commentary: CEO Patrick J. Haveron noted that while investment income improved, underwriting losses were driven by adverse development in run-off portfolios. The company is adjusting its investment focus toward income-producing, lower-risk assets due to market uncertainty.
- Capital Strategy: Maiden expects to continue a disciplined approach to share repurchases under its remaining $72.7 million authorization (as of Sept 30, 2023). A separate $100 million authorization exists for Senior Notes repurchases.
- Tax Assets: The balance sheet does not reflect $121.0 million in net U.S. deferred tax assets (including $304.9 million in NOLs) due to a full valuation allowance. Management believes recognition is possible in the future as current income increases.
- Risks: Key risks include continued adverse loss development in run-off lines (specifically Hospital Liability and German auto programs), economic uncertainty affecting alternative investment monetization, and the timing of deferred tax asset recognition.
Investor Verification Checklist
- Verify the magnitude and duration of adverse loss development in the AmTrust Hospital Liability line, specifically regarding pre-2016 losses not covered by reinsurance.
- Confirm the sustainability of the 36-39% increase in net investment income as interest rates stabilize or fluctuate.
- Review the status of the $121.0 million net U.S. deferred tax assets and the criteria required to release the full valuation allowance.
- Monitor the pace of share repurchases against the remaining $72.7 million authorization and the impact on book value per share.
- Assess the run-off trajectory of the Diversified Reinsurance segment, particularly the German auto program and older treaty programs.